GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (FRA:2GH) » Definitions » Institutional Ownership

Merus NV (FRA:2GH) Institutional Ownership : 24.77% (As of Jun. 10, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Merus NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Merus NV's institutional ownership is 24.77%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Merus NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Merus NV's Float Percentage Of Total Shares Outstanding is 99.43%.


Merus NV Institutional Ownership Historical Data

The historical data trend for Merus NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Institutional Ownership Chart

Merus NV Historical Data

The historical data trend for Merus NV can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 33.90 30.58 31.22 32.39 31.61 30.98 30.16 26.97 28.45 24.77

Merus NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Merus NV (FRA:2GH) Business Description

Industry
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV (FRA:2GH) Headlines

No Headlines